Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations-Reference-Cited by-同舟云学术

Oritavancin use in patients with recurrent bone infections by methicillin-resistant Staphylococcus aureus with monitoring of concentrations

Published:2024-05-14 Issue:7 Volume:43 Page:1503-1504
ISSN:0934-9723
Container-title:European Journal of Clinical Microbiology & Infectious Diseases
language:en
Short-container-title:Eur J Clin Microbiol Infect Dis

Author:

Bongiovanni Marco,Thoueille Paul,Barda Beatrice,Mercier Thomas,Marzolini Catia,Ramponi Niccolò,Choong Eva,Cantù Marco,Decosterd Laurent A.,Bernasconi Enos

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10096-024-04844-5.pdf

Reference5 articles.

1. McKay GA, Beaulieu S, Arhin FF et al (2009) Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 63:1191–1199. https://doi.org/10.1093/jac/dkp126

2. Corey GR, Kabler H, Mehra P et al (2014) Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 370:2180–2190. https://doi.org/10.1056/NEJMoa1310422

3. Corey GR, Good S, Jiang H et al (2014) Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis 60:254–262. https://doi.org/10.1093/cid/ciu778

4. Lupia T, De Benedetto I, Bosio R et al (2023) Role of oritavancin in the treatment of infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans: narrative review and possible developments. Life 13:959. https://doi.org/10.3390/life13040959

5. Chastain DB, Davis A (2019) Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review. Int J Antimicrob Agents 53:429–434. https://doi.org/10.1016/j.ijantimicag.2018.11.023